Bal Pharma profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Jun 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |||||
|---|---|---|---|---|---|---|
| 7.9% | 7.9% | 9.8% | 11.1% | 4.1% | ||
| 1.8% | 1.8% | 2.2% | 2.4% | 0.8% | ||
| 17.2% | 17.2% | 17.0% | 19.5% | 15.4% | ||
| 9.5% | 8.8% | 8.9% | 8.9% | 4.6% | ||
Margins | ||||||
| 10.1% | 10.2% | 9.8% | 9.3% | 8.3% | ||
| 6.7% | 6.7% | 6.5% | 6.3% | 5.3% | ||
| — | 12.1% | 4.6% | 15.6% | — | ||
| 2.1% | 1.9% | 1.7% | 2.7% | 1.6% | ||
| 2.2% | 2.0% | 2.4% | 2.2% | 0.9% | ||
| 2.2% | 2.0% | 2.4% | 2.2% | 0.9% | ||
| 3.9% | 3.9% | 6.8% | 97.0% | 7.6% | ||
Additional | ||||||
| −5.6% | −6.5% | −40.9% | 17.7% | 44.8% | ||
| — | 30.2% | 0.0% | 0.0% | 0.0% | ||
| 7.9% | 5.5% | 9.8% | 11.1% | 4.1% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.